Truist Securities Reiterates Buy on Genmab, Raises Price Target to $67
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $67.
Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $67.
